Laboratory Corp. Of America Holdings LH
The next Laboratory Corp. Of America Holdings dividend is expected to go ex in 2 months and to be paid in 2 months.
The previous Laboratory Corp. Of America Holdings dividend was 72c and it went ex 2 months ago and it was paid 23 days ago.
There are typically 4 dividends per year (excluding specials).
|Summary||Previous dividend||Next dividend|
|Per share||72c||Sign Up Required|
|Declaration date||14 Jul 2022 (Thu)||07 Oct 2022 (Fri)|
|Ex-div date||17 Aug 2022 (Wed)||17 Nov 2022 (Thu)|
|Pay date||09 Sep 2022 (Fri)||09 Dec 2022 (Fri)|
Enter the number of Laboratory Corp. Of America Holdings shares you hold and we'll calculate your dividend payments:
Sign up for Laboratory Corp. Of America Holdings and we'll email you the dividend information when they declare.
Add Laboratory Corp. Of America Holdings to receive free notifications when they declare their dividends.
Your account is set up to receive Laboratory Corp. Of America Holdings notifications.
|Status||Type||Decl. date||Ex-div date||Pay date||Decl. Currency||Forecast amount||Decl. amount||Accuracy|
|Forecast||Quarterly||31 Dec 2026||11 Feb 2027||05 Mar 2027||USD||Sign up||—|
|Forecast||Quarterly||02 Oct 2026||12 Nov 2026||04 Dec 2026||USD||Sign up||—|
|Forecast||Quarterly||02 Jul 2026||13 Aug 2026||04 Sep 2026||USD||Sign up||—|
|Forecast||Quarterly||02 Apr 2026||13 May 2026||04 Jun 2026||USD||Sign up||—|
|Forecast||Quarterly||01 Jan 2026||12 Feb 2026||06 Mar 2026||USD||Sign up||—|
|Forecast||Quarterly||03 Oct 2025||13 Nov 2025||05 Dec 2025||USD||Sign up||—|
|Forecast||Quarterly||03 Jul 2025||14 Aug 2025||05 Sep 2025||USD||Sign up||—|
|Forecast||Quarterly||03 Apr 2025||14 May 2025||05 Jun 2025||USD||Sign up||—|
|Forecast||Quarterly||02 Jan 2025||13 Feb 2025||07 Mar 2025||USD||Sign up||—|
|Forecast||Quarterly||04 Oct 2024||14 Nov 2024||06 Dec 2024||USD||Sign up||—|
|Forecast||Quarterly||04 Jul 2024||15 Aug 2024||06 Sep 2024||USD||Sign up||—|
|Forecast||Quarterly||04 Apr 2024||15 May 2024||06 Jun 2024||USD||Sign up||—|
|Forecast||Quarterly||04 Jan 2024||15 Feb 2024||08 Mar 2024||USD||Sign up||—|
|Forecast||Quarterly||06 Oct 2023||16 Nov 2023||08 Dec 2023||USD||Sign up||—|
|Forecast||Quarterly||06 Jul 2023||17 Aug 2023||08 Sep 2023||USD||Sign up||—|
|Forecast||Quarterly||06 Apr 2023||17 May 2023||08 Jun 2023||USD||Sign up||—|
|Forecast||Quarterly||05 Jan 2023||16 Feb 2023||10 Mar 2023||USD||Sign up||—|
|Forecast||Quarterly||07 Oct 2022||17 Nov 2022||09 Dec 2022||USD||Sign up||—|
|Paid||Quarterly||14 Jul 2022||17 Aug 2022||09 Sep 2022||USD||72c||72c||😄|
|Paid||Quarterly||07 Apr 2022||18 May 2022||09 Jun 2022||USD||—||72c|
|2022||Sign Up Required|
|2023||Sign Up Required|
|2024||Sign Up Required|
|2025||Sign Up Required|
|2026||Sign Up Required|
Laboratory Corp. Of America Holdings Optimized Dividend Chart
About Laboratory Corp. Of America Holdings
Laboratory Corporation of America Holdings, incorporated on March 8, 1994, is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The Company serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers (such as physician assistants and nurse practitioners), hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies and independent clinical laboratories.
LabCorp Diagnostics Segment
The Company's LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. As of December 31, 2016, its network was supported by an information technology system, local labs offering rapid response testing and approximately 1,750 patient service centers (PSCs) strategically located throughout the United States to provide convenient access to testing services. In addition to diagnostic testing, LCD also offers a range of other testing services, including forensic deoxyribonucleic acid (DNA) analysis, food safety and integrity services, as well as occupational and wellness testing for employers. As of December 31, 2016, it offered a test menu, including more than 4,800 clinical, anatomic pathology, genetic and genomic tests.
As of December 31, 2016, LCD offered a menu of over 4,800 tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, prostate-specific antigen (PSA), sexually transmitted disease (STD) tests, hepatitis C (HCV) tests, Vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. In addition, LCD provides a range of specialty testing services in the areas of allergy, diagnostic genetics, women's health, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology and pain management. LCD also performs a range of other testing, including employment and occupational testing, DNA testing to determine parentage and to assist in forensic investigations, environmental testing, wellness testing, toxicology testing, pain management testing. LCD also provides services to the food, beverage, nutraceutical, animal feed, chemical and agrochemical industries, which include nutritional analysis and equivalency, nutritional content fact labels, microbiological and chemical contaminant safety analysis, product development solutions, sensory testing, pilot manufacturing, pesticide screening and stability testing.
LCD offers tumor tissue analysis, including immunohistochemistry (IHC), cancer cytogenetics and fluorescence in situ hybridization (FISH), through its Dianon Pathology and Integrated Oncology specialty testing laboratories. LCD's cardiovascular menu includes core cholesterol tests, expanded lipid profiles, a metabolic syndrome profile and tests for thrombosis and stroke. LCD also offers complete testing for monitoring disease progression and response to therapy, including the clinical decision support (CDS) reports available through Litholink. LCD offers a menu of tests for hemostasis and thrombosis, including bleeding profiles and screening tests, profiles for reproductive health, factor analysis, thrombin generation markers and thrombotic risk evaluation. LCD offers cytogenetic, molecular cytogenetic, biochemical and molecular genetic tests. The biochemical genetics offerings include a rage of prenatal screening options, including integrated and sequential prenatal assays and non-invasive prenatal testing (NIPT) for sensitive and earlier assessment of risk for multiple fetal chromosomal aneuploidies, such as Down syndrome.
LCD is a provider of advanced hormone/steroid testing, including services for the endocrine specialist. LCD provides complete human immunodeficiency virus (HIV) testing services, including viral load measurements, genotyping and phenotyping and host genetic factors. It also provides resistance tests, including PhenoSense, PhenoSenseGT, Trofile and GenoSure PRIme. LCD offers a menu of women's health testing, including NuSwab STD testing, as well as liquid-based Pap testing with image-guided cervical cytology for improved cervical cancer detection, and out-of-the-vial Pap testing with options for human papillomavirus (HPV). LCD also offers tests and technologies for reproductive care, including maternal serum screening, prenatal diagnostics, ethnicity carrier screening, testing for causes of infertility or miscarriage and postnatal testing services. LCD provides forensic identity testing used in connection with criminal proceedings and parentage evaluation services that assist in determining parentage for child support enforcement proceedings and determining genetic relationships for immigration purposes. LCD provides testing services for the detection of drug and alcohol abuse for private and government customers.
Covance Drug Development Segment
The Company's CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. CDD's early development service offerings include research models, lead optimization, analytical services, safety assessment, and chemistry manufacturing and control (CMC) services for drug development. CDD also offers solution-based approaches by leveraging program development directors and project managers to help guide strategic decisions and manage molecule development in an integrated, streamlined manner across CDD's eight analytical laboratories and preclinical laboratories in the United States, the United Kingdom, Germany and China. CDD's offerings in preclinical area include technologies, such as MarketPlace and StudyTracker. Covance MarketPlace is a private, secure Web portal providing potential investors or partners access to information about new drugs in development. StudyTracker is an Internet-based customer access product, allowing customers of toxicology, bioanalytical, metabolism, and reproductive and developmental toxicology services to review study schedules and data on a near real-time basis.
CDD's analytical services offering include liquid chromatography-mass spectroscopy (LC-MS) immunoanalytical solutions and specialty support, translational biomarker solutions, discovery bioanalysis, vaccine analysis, and organic synthesis. CDD has lab facilities across over three continents providing in vitro drug metabolism, in vivo radiolabeled absorption, distribution, metabolism and excretion studies, metabolite identification/profiling and non-clinical pharmacokinetic (PK) screening in addition to radiosynthesis services. CDD also provides pharmaceutical chemistry services that determine the metabolic profile and bioavailability of drug candidates. CMC offers packages supporting the United States Food and Drug Administration (FDA) Investigational New Drug Application and New Drug Application/Biologic License Application submissions, as well as programs to help CDD's clients meet acceptance criteria for the release of drug product for both biologics and small molecules. It also offers early phase development solutions (EPDS).
Through its global network of central laboratories in the United States, Switzerland, Belgium, Singapore and China, CDD provides central laboratory testing services to biopharmaceutical customers. In addition to safety testing, CDD offers range of specialty testing capabilities, spanning the clinical development continuum. These include applied applied genomics, next-generation sequencing, anatomic pathology and histology, flow cytometry, clinical immunoassays, as well as preclinical and exploratory biomarker development. CDD offers a range of clinical trial services, including the full management of Phase I through IV clinical studies. CDD provides clinical pharmacology services, including first-in-human trials, and early clinical trial subject proof-of-concept studies of new pharmaceuticals.
CDD offers a range of commercialization solutions, which include life cycle management and post-approval studies, which are conducted after a drug has undergone clinical efficacy and safety testing and the New Drug Application has been submitted to the FDA and/or other regulatory bodies. CDD also offers market access solutions, including reimbursement consulting and hotlines, patient assistance programs, health economic and outcomes research services, observational studies, real world evidence and analytics services and value communication services. CDD's Xcellerate informatics platform integrates multiple sources of data to deliver information throughout the course of client studies. Xcellerate Forecasting & Site Selection enables customers to identify the optimal sites and investigators.
The Company competes with Health Diagnostic Laboratory, Inc. and Singulex, Inc.
- Pharmaceuticals & Biotechnology
- United States
- Share Price
- $204.81 (yesterday's closing price)
- Shares in Issue
- 93 million
- Market Cap
- Market Indices
- S&P 500